サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1777327

酵素補充療法の世界市場

Enzyme Replacement Therapy

出版日
ページ情報
英文 378 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=147.69円
酵素補充療法の世界市場
出版日: 2025年07月28日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 378 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

酵素補充療法の世界市場は2030年までに157億米ドルに到達

2024年に101億米ドルと推定される酵素補充療法の世界市場は、2024年から2030年にかけてCAGR 7.7%で成長し、2030年には157億米ドルに達すると予測されます。本レポートで分析したセグメントの一つであるゴーシェ病は、CAGR5.5%を記録し、分析期間終了時には41億米ドルに達すると予測されます。MPS分野の成長率は、分析期間中CAGR 9.7%と推定されます。

米国市場は27億米ドル、中国はCAGR11.7%で成長予測

米国の酵素補充療法市場は、2024年に27億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに33億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは11.7%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ4.0％と7.3％と予測されています。欧州では、ドイツがCAGR 5.1%で成長すると予測されています。

世界の酵素補充療法市場- 主要動向と促進要因のまとめ

酵素補充療法は希少疾患治療をどう変えるか？

酵素補充療法（ERT）は、代謝機能不全につながる酵素欠損に対処することで、希少遺伝性疾患の治療に革命をもたらしています。ERTは、ゴーシェ病、ファブリー病、ポンペ病などのライソゾーム貯蔵障害（LSD）で広く使用されており、患者は正常な細胞機能に必要な特定の酵素を欠いています。ERTは、組換え酵素や生物工学的に設計された酵素を供給することにより、代謝バランスを回復させ、疾患の進行を抑え、患者の予後を改善します。

遺伝性代謝疾患の有病率の増加とバイオテクノロジーの進歩により、より効果的で標的を絞った酵素療法の開発が進んでいます。ペグ化酵素や長時間作用型ERTなどの製剤の改良により、治療効果が向上し、点滴回数が減少しています。さらに、新生児スクリーニング・プログラムや早期診断イニシアチブの拡大により、ERTの恩恵を受けられる患者の迅速な特定が可能になり、より良い疾患管理とQOLの向上につながっています。

酵素補充療法の将来を牽引するイノベーションとは？

遺伝子治療と標的ドラッグデリバリーにおける最近の進歩が、酵素補充療法の将来を形成しています。研究者は、酵素の安定性と組織への浸透を改善し、治療効果を高める新しい薬剤製剤を探求しています。リポソームやナノ粒子をベースとしたデリバリー・システムは、標的細胞への酵素の取り込みを改善し、治療効果を制限する免疫系反応を軽減するために開発されています。

CRISPRやウイルスベクターベースの遺伝子治療などの遺伝子編集技術も、ERTの代替または補完的治療の可能性として研究されています。これらのアプローチは、機能的な遺伝子を患者細胞に導入することにより、長期的または永続的な酵素補正を行うことを目的としています。バイオテクノロジーが進歩し続けるにつれて、次世代の酵素補充療法は、希少な遺伝性疾患に対して、より効果的で個別化された耐久性のある治療選択肢を提供する可能性があります。

酵素補充療法市場の成長を促進する主な要因は何か？

酵素補充療法市場の成長は、希少遺伝性疾患に対する認識の高まり、バイオ医薬品製造の進歩、新興市場におけるヘルスケアアクセスの拡大など、いくつかの要因によってもたらされます。希少疾患治療に対する政府の優遇措置や希少疾病用医薬品の指定は、製薬会社によるERT開発への投資を促しています。また、新生児スクリーニング・プログラムや遺伝子検査イニシアチブの増加も、早期診断と治療導入に寄与しています。

さらに、細胞培養技術や組換えタンパク質生産などの生物製剤製造の進歩が、酵素補充療法の拡張性と手頃な価格を向上させています。個別化医療や精密治療への投資の拡大は、市場拡大をさらに後押ししています。新たな治療アプローチが登場する中、ERTは希少疾患管理の要であり続け、これまで治療不可能であった病態の患者に希望をもたらすと期待されています。

セグメント

治療状態（ゴーシェ病、MPS、SCID、ポンペ病、ファブリー病、その他）、投与経路（非経口、経口）、エンドユーザー（輸液センター、病院、その他）

調査対象企業の例

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • Anthera Pharmaceuticals
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Denali Therapeutics Inc.
  • GC Biopharma
  • Horizon Therapeutics plc
  • JCR Pharmaceuticals Co., Ltd.
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • PTC Therapeutics
  • Recordati Rare Diseases Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Swedish Orphan Biovitrum AB（Sobi）
  • Synageva BioPharma Corp.
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.

AI統合

当社は、有効な専門家コンテンツとAIツールにより、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界固有のSLMをクエリする代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP30809

Global Enzyme Replacement Therapy Market to Reach US$15.7 Billion by 2030

The global market for Enzyme Replacement Therapy estimated at US$10.1 Billion in the year 2024, is expected to reach US$15.7 Billion by 2030, growing at a CAGR of 7.7% over the analysis period 2024-2030. Gaucher Disease, one of the segments analyzed in the report, is expected to record a 5.5% CAGR and reach US$4.1 Billion by the end of the analysis period. Growth in the MPS segment is estimated at 9.7% CAGR over the analysis period.

The U.S. Market is Estimated at US$2.7 Billion While China is Forecast to Grow at 11.7% CAGR

The Enzyme Replacement Therapy market in the U.S. is estimated at US$2.7 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$3.3 Billion by the year 2030 trailing a CAGR of 11.7% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 4.0% and 7.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.1% CAGR.

Global Enzyme Replacement Therapy Market - Key Trends & Drivers Summarized

How Is Enzyme Replacement Therapy Transforming Rare Disease Treatment?

Enzyme replacement therapy (ERT) is revolutionizing the treatment of rare genetic disorders by addressing enzyme deficiencies that lead to metabolic dysfunction. ERT is widely used in lysosomal storage disorders (LSDs), such as Gaucher disease, Fabry disease, and Pompe disease, where patients lack specific enzymes required for normal cellular function. By providing recombinant or bioengineered enzymes, ERT helps restore metabolic balance, reducing disease progression and improving patient outcomes.

The increasing prevalence of inherited metabolic disorders and advancements in biotechnology have led to the development of more effective and targeted enzyme therapies. Improved formulations, including pegylated enzymes and long-acting ERTs, are enhancing treatment efficacy and reducing infusion frequency. Additionally, the expansion of newborn screening programs and early diagnostic initiatives is enabling faster identification of patients who can benefit from ERT, leading to better disease management and improved quality of life.

What Are the Innovations Driving the Future of Enzyme Replacement Therapy?

Recent advancements in gene therapy and targeted drug delivery are shaping the future of enzyme replacement therapy. Researchers are exploring novel drug formulations that improve enzyme stability and tissue penetration, enhancing therapeutic outcomes. Liposomal and nanoparticle-based delivery systems are being developed to improve enzyme uptake by target cells and reduce immune system responses that may limit treatment efficacy.

Gene editing technologies such as CRISPR and viral vector-based gene therapy are also being investigated as potential alternatives or complementary treatments to ERT. These approaches aim to provide long-term or permanent enzyme correction by introducing functional genes into patient cells. As biotechnology continues to advance, the next generation of enzyme replacement therapies may offer more effective, personalized, and durable treatment options for rare genetic disorders.

What Are the Key Factors Driving Growth in the Enzyme Replacement Therapy Market?

The growth in the enzyme replacement therapy market is driven by several factors, including increasing awareness of rare genetic disorders, advancements in biopharmaceutical manufacturing, and expanding healthcare access in emerging markets. Government incentives and orphan drug designations for rare disease treatments are encouraging pharmaceutical companies to invest in ERT development. The rise in newborn screening programs and genetic testing initiatives is also contributing to early diagnosis and treatment adoption.

Additionally, advancements in biologics manufacturing, including cell culture technologies and recombinant protein production, are improving the scalability and affordability of enzyme replacement therapies. The growing investment in personalized medicine and precision therapeutics is further driving market expansion. As new treatment approaches emerge, ERT is expected to remain a cornerstone of rare disease management, offering hope to patients with previously untreatable conditions.

SCOPE OF STUDY:

The report analyzes the Enzyme Replacement Therapy market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutic Condition (Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease, Others); Administration Route (Parenteral, Oral); End-Use (Infusion Centers, Hospitals, Others)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 39 Featured) -

  • AbbVie Inc.
  • Alexion Pharmaceuticals, Inc.
  • Amicus Therapeutics
  • Anthera Pharmaceuticals
  • BioMarin Pharmaceutical Inc.
  • Chiesi Farmaceutici S.p.A.
  • Denali Therapeutics Inc.
  • GC Biopharma
  • Horizon Therapeutics plc
  • JCR Pharmaceuticals Co., Ltd.
  • Pfizer Inc.
  • Protalix BioTherapeutics, Inc.
  • PTC Therapeutics
  • Recordati Rare Diseases Inc.
  • Sangamo Therapeutics, Inc.
  • Sanofi
  • Swedish Orphan Biovitrum AB (Sobi)
  • Synageva BioPharma Corp.
  • Takeda Pharmaceutical Company
  • Ultragenyx Pharmaceutical Inc.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Enzyme Replacement Therapy - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Prevalence of Rare Lysosomal Storage Disorders Propels Demand for Enzyme Replacement Therapies
    • Advancements in Genomic Research Strengthen the Business Case for Personalized ERT Approaches
    • Increasing Awareness and Early Diagnosis of Rare Diseases Accelerates Demand for Therapeutic Enzymes
    • Regulatory Incentives and Orphan Drug Designations Expand Addressable Market Opportunities
    • Integration of Biomarker-Based Diagnostic Tools Drives Adoption of Tailored ERT Protocols
    • Innovations in Recombinant DNA Technology Spur Growth in Novel ERT Product Development
    • Strategic Collaborations Between Biotech Firms and Academia Accelerate Pipeline Expansion
    • Expansion of Healthcare Access in Emerging Markets Throws the Spotlight on Unmet Treatment Needs
    • Rapid Technological Advancements in Drug Delivery Systems Drive Patient Compliance and Market Uptake
    • Increasing Funding for Rare Disease Research Sustains Long-Term Growth Prospects for ERT
    • Favorable Reimbursement Policies in Developed Markets Strengthen the Business Case for Commercial Launches
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Enzyme Replacement Therapy Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Enzyme Replacement Therapy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Gaucher Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Gaucher Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for MPS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for MPS by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for MPS by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for SCID by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for SCID by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for SCID by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Pompe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Pompe Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Pompe Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Fabry Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Fabry Disease by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Fabry Disease by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Therapeutic Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Therapeutic Conditions by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Therapeutic Conditions by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Other Administration Routes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Other Administration Routes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Infusion Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Infusion Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 32: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 33: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 35: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 36: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 38: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: USA Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: USA 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 41: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: USA Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: USA 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 44: USA Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: USA Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: USA 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 47: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Canada Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Canada 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 50: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: Canada Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: Canada 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 53: Canada Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: Canada Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: Canada 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • JAPAN
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 56: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 57: Japan Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Japan 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 59: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Japan Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Japan 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 62: Japan Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Japan Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Japan 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • CHINA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 65: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: China Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: China 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 68: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: China Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: China 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 71: China Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: China Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: China 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • EUROPE
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 74: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 75: Europe Historic Review for Enzyme Replacement Therapy by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Europe 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 77: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Europe Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Europe 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 80: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Europe Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Europe 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 83: Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: Europe Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: Europe 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • FRANCE
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 86: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: France Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: France 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 89: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: France Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: France 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 92: France Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: France Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: France 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • GERMANY
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 95: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Germany Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Germany 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 98: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Germany Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Germany 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 101: Germany Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Germany Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Germany 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 104: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Italy Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Italy 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 107: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 108: Italy Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Italy 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 110: Italy Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Italy Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Italy 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 113: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: UK Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: UK 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 116: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: UK Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: UK 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 119: UK Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: UK Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: UK 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 122: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: Spain Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: Spain 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 125: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: Spain Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: Spain 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 128: Spain Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: Spain Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: Spain 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 131: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: Russia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: Russia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 134: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Russia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Russia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 137: Russia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Russia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Russia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 141: Rest of Europe Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 143: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Rest of Europe Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 146: Rest of Europe Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Rest of Europe Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Rest of Europe 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 150: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 155: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Asia-Pacific Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 158: Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Asia-Pacific Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 161: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Australia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Australia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 164: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Australia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Australia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 167: Australia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Australia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Australia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • INDIA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 170: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: India Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: India 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 173: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 174: India Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: India 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 176: India Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: India Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: India 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 179: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: South Korea Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: South Korea 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 182: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: South Korea Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: South Korea 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 185: South Korea Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: South Korea Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: South Korea 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 191: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 194: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Rest of Asia-Pacific Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Rest of Asia-Pacific 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 197: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 198: Latin America Historic Review for Enzyme Replacement Therapy by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 200: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: Latin America Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 203: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: Latin America Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: Latin America 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 206: Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Latin America Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Latin America 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 209: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Argentina Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Argentina 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 212: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Argentina Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Argentina 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 215: Argentina Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Argentina Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Argentina 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 218: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 219: Brazil Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 220: Brazil 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 221: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 222: Brazil Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 223: Brazil 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 224: Brazil Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 225: Brazil Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 226: Brazil 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 227: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 228: Mexico Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 229: Mexico 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 230: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 231: Mexico Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 232: Mexico 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 233: Mexico Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 234: Mexico Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 235: Mexico 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 237: Rest of Latin America Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 238: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 239: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 240: Rest of Latin America Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 241: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 242: Rest of Latin America Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 243: Rest of Latin America Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 244: Rest of Latin America 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 245: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 246: Middle East Historic Review for Enzyme Replacement Therapy by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 247: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 248: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 249: Middle East Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 250: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 251: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 252: Middle East Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 253: Middle East 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 254: Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 255: Middle East Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 256: Middle East 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 257: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 258: Iran Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 259: Iran 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 260: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 261: Iran Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 262: Iran 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 263: Iran Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 264: Iran Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 265: Iran 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 266: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 267: Israel Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 268: Israel 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 269: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 270: Israel Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 271: Israel 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 272: Israel Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 273: Israel Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 274: Israel 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 276: Saudi Arabia Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 277: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 278: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 279: Saudi Arabia Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 280: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 281: Saudi Arabia Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 282: Saudi Arabia Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 283: Saudi Arabia 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 284: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 285: UAE Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 286: UAE 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 287: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 288: UAE Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 289: UAE 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 290: UAE Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 291: UAE Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 292: UAE 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 294: Rest of Middle East Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 295: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 296: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 297: Rest of Middle East Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 298: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 299: Rest of Middle East Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 300: Rest of Middle East Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 301: Rest of Middle East 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030
  • AFRICA
    • Enzyme Replacement Therapy Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 302: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 303: Africa Historic Review for Enzyme Replacement Therapy by Therapeutic Condition - Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 304: Africa 15-Year Perspective for Enzyme Replacement Therapy by Therapeutic Condition - Percentage Breakdown of Value Sales for Gaucher Disease, MPS, SCID, Pompe Disease, Fabry Disease and Other Therapeutic Conditions for the Years 2015, 2025 & 2030
    • TABLE 305: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 306: Africa Historic Review for Enzyme Replacement Therapy by End-Use - Hospitals, Other Administration Routes and Infusion Centers Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 307: Africa 15-Year Perspective for Enzyme Replacement Therapy by End-Use - Percentage Breakdown of Value Sales for Hospitals, Other Administration Routes and Infusion Centers for the Years 2015, 2025 & 2030
    • TABLE 308: Africa Recent Past, Current & Future Analysis for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 309: Africa Historic Review for Enzyme Replacement Therapy by Administration Route - Parenteral and Oral Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 310: Africa 15-Year Perspective for Enzyme Replacement Therapy by Administration Route - Percentage Breakdown of Value Sales for Parenteral and Oral for the Years 2015, 2025 & 2030

IV. COMPETITION